IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma

International Journal of Cancer

Volumn 129, Issue 10, 2011, Pages 2360-2369

  Ueno, Koji ^a   Hirata, Hiroshi ^a   Majid, Shahana ^a   Tabatabai, Z Laura ^a   Hinoda, Yuji ^b   Dahiya, Rajvir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

catenin; IGFBP 4; metastasis; RCC; TOPflash

Indexed keywords

BETA CATENIN; M CAM PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 4; TUMOR MARKER; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CARCINOGENESIS; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IGFBP4 GENE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH;

ANTIGENS, CD146; BETA CATENIN; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFECTION; WNT PROTEINS;

EID: 80052877620     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25899     Document Type: Article

References (32)

1. Moon RT, Kohn AD, De Ferrari GV, Kaykas A,. WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 2004; 5: 691-701. (Pubitemid 39150127)
2. Clevers H,. Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469-80.
3. Cohen ED, Tian Y, Morrisey EE,. Wnt signaling: an essential regulator of cardiovascular differentiation, morphogenesis and progenitor selfrenewal. Development 2008: 135: 789-98. (Pubitemid 351524132)
4. Ravindranath A, O'Connell A, Johnston PG, El-Tanani MK,. The role of LEF/TCF factors in neoplastic transformation. Curr Mol Med 2008; 8: 38-50. (Pubitemid 351516823)
5. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 417-22. (Pubitemid 38437267)
6. Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, Kikuno N, Tanaka Y, Majid S, Nakagawa M, Igawa M, Dahiya R,. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006; 12: 6989-97. (Pubitemid 44974494)
7. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Kawakami K, Yamamura S, Ueno K, Majid S, Saini S, Ishii N, Dahiya R,. Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res 2009; 15: 5678-87.
8. Hirata H, Hinoda Y, Ueno K, Majid S, Saini S, Dahiya R,. Role of Secreted Frizzled-Related Protein 3 (sFRP3) in human renal cell carcinoma. Cancer Res 2010; 70: 1896-905.
9. Zhu W, Shiojima I, Ito Y, Li Z, Ikeda H, Yoshida M, Naito AT, Nishi J, Ueno H, Umezawa A, Minamino T, Nagai T, et al. IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature 2008; 454: 345-9.
10. Durai R, Davies M, Yang W, Yang SY, Seifalian A, Goldspink G, Winslet M,. Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). Int J Oncol 2006; 28: 1317-25.
11. Yu H, Rohan T,. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-89.
12. Cheung C, Vesey D, Cotterill A,. Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. Int J Urol 2005; 12: 17-28. (Pubitemid 40332998)
13. Chuang ST, Patton KT, Schafernak KT, Papavero V, Lin F, Baxter RC, The BT, Yang XJ,. Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. J Urol 2008; 179: 445-9.
14. Ueno K, Hiura M, Suehiro Y, Hazama S, Hirata H, Oka M, Imai K, Dahiya R, Hinoda Y,. Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia 2008; 10: 697-705. (Pubitemid 351883886)
15. Ueno K, Hazama S, Mitomori S, Nishioka M, Suehiro Y, Hirata H, Oka M, Imai K, Dahiya R, Hinoda Y,. Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br J Cancer 2009; 101: 1374-81.
16. Zumkeller W, Schwander J, Mitchell CD, Morrell DJ, Schofield PN, Preece MA,. Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumour. Eur J Cancer 1993; 29A: 1973-7. (Pubitemid 23324355)
17. Wegmann BR, Schöneberger HJ, Kiefer PE, Jaques G, Brandscheid D, Havemann K,. Molecular cloning of IGFBP-5 from SCLC cell lines and expression of IGFBP-4, IGFBP-5 and IGFBP-6 in lung cancer cell lines and primary tumours. Eur J Cancer 1993; 29: 1578-84. (Pubitemid 23251801)
18. Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY,. Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer 2001; 37: 2257-63. (Pubitemid 33001298)
19. Damon SE, Maddison L, Ware JL, Plymate SR,. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology 1998; 139: 3456-64. (Pubitemid 28512302)
20. Culouscou JM, Shoyab M,. Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein. Cancer Res 1991; 51: 2813-9.
21. Diehl D, Hoeflich A, Wolf E, Lahm, H., Insulin-like growth factor (IGF)-binding protein-4 inhibits colony formation of colorectal cancer cells by IGF-independent mechanisms. Cancer Res 2004; 64: 1600-3. (Pubitemid 38428678)
22. Bartling B, Koch A, Simm A, Scheubel R, Silber RE, Santos AN,. Insulin-like growth factor binding proteins-2 and -4 enhance the migration of human CD34-/CD133+ hematopoietic stem and progenitor cells. Int J Mol Med 2010; 25: 89-96.
23. Lehmann JM, Riethmüller G, Johnson JP,. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 1989; 86: 9891-5. (Pubitemid 20030740)
24. Vainio O, Dunon D, Aïssi F, Dangy JP, McNagny KM, Imhof BA,. HEMCAM, an adhesion molecule expressed by c-kit+ hemopoietic progenitors. J Cell Biol 1996; 135: 1655-68. (Pubitemid 26427659)
25. Filshie RJ, Zannettino AC, Makrynikola V, Gronthos S, Henniker AJ, Bendall LJ, Gottlieb DJ, Simmons PJ, Bradstock KF,. MUC18, a member of the immunoglobulin superfamily, is expressed on bone marrow fibroblasts and a subset of hematological malignancies. Leukemia 1998; 12: 414-21. (Pubitemid 28138227)
26. Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F, Chabannon C,. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res 2009; 11: R1.
27. Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, Zeni B, Griso C, Pegoraro C, Zannoni M, Gariboldi M, Balladore E, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer 2006; 119: 1920-6. (Pubitemid 44356852)
28. Kessenbrock K, Plaks V, Werb Z,. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
29. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y,. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002; 21: 5861-7. (Pubitemid 35007236)
30. Petrella BL, Lohi J, Brinckerhoff CE,. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 2005; 24: 1043-52. (Pubitemid 40313881)
31. Kim YS, Kang YK, Kim JB, Han SA, Kim KI, Paik SR,. beta-catenin expression and mutational analysis in renal cell carcinomas. Pathol Int 2000; 50: 725-30.
32. Schips L, Zigeuner R, Ratschek M, Rehak P, Rüschoff J, Langner C,. Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol 2004; 122: 931-7. (Pubitemid 39577362)